Celevac 500 mg tablets

  • Name:

    Celevac 500 mg tablets

  • Company:
    info
  • Active Ingredients:

    Methylcellulose

  • Legal Category:

    Supply through pharmacy only

Summary of Product Characteristics last updated on medicines.ie: 7/8/2015
print

Print ViewKeyword Search SmPC

ADVANZ Pharma

advanz-full-rgb_1543842253

Company Products

Medicine NameActive Ingredients
Medicine Name Celevac 500 mg tablets Active Ingredients Methylcellulose
Medicine Name Chloromycetin 0.5% w/v Redidrops Eye Drops, Solution. Active Ingredients Chloramphenicol
Medicine Name Clarithromycin 500 mg, Powder for Concentrate for Solution for Infusion Active Ingredients Clarithromycin lactobionate
Medicine Name Codipar 15mg/500mg Capsules Active Ingredients Codeine Phosphate, Paracetamol
Medicine Name Codipar 15mg/500mg Capsules Active Ingredients Codeine Phosphate Hemihydrate, Paracetamol
Medicine Name Codipar 15mg/500mg Effervescent Tablets Active Ingredients Codeine Phosphate Hemihydrate, Paracetamol
Medicine Name Cyclimorph 10 Injection Active Ingredients Cyclizine tartrate, Morphine Tartrate
Medicine Name Cyclimorph 15 Solution for Injection Active Ingredients Cyclizine tartrate, Morphine Tartrate
Medicine Name Detrunorm XL 30 mg modified-release capsules Active Ingredients Propiverine hydrochloride
Medicine Name Eltroxin 100 microgram Tablets Active Ingredients Levothyroxine sodium
Medicine Name Eltroxin 50 microgram Tablets Active Ingredients Levothyroxine sodium
Medicine Name Erythrocin 250mg Tablets Active Ingredients Erythromycin Stearate
Medicine Name Erythrocin 500mg Tablets Active Ingredients Erythromycin Stearate
Medicine Name Erythrocin IV Lactobionate 1.0g Powder for Solution for Infusion Active Ingredients Erythromycin Lactobionate
Medicine Name Erythromycin Tablets BP 250mg. Active Ingredients Erythromycin
Medicine Name Erythroped Adult Tablets Active Ingredients Erythromycin Ethylsuccinate
Medicine Name Erythroped Forte SF 500mg/5ml granules for oral suspension Active Ingredients Erythromycin Ethylsuccinate
Medicine Name Erythroped PI SF 125mg/5ml granules for oral suspension Active Ingredients Erythromycin Ethylsuccinate
Medicine Name Erythroped SF 250mg/5ml granules for oral suspension Active Ingredients Erythromycin Ethylsuccinate
Medicine Name Fucithalmic 10 mg/g Viscous eye drops, suspension Active Ingredients Fusidic Acid Hemihydrate
Medicine Name Genticin 80 mg/2 ml Solution for Injection Active Ingredients Gentamicin sulfate
Medicine Name Genticin Eye/Ear Drops Solution Active Ingredients Gentamicin sulfate
Medicine Name Gentisone HC 0.3% w/v & 1.0% w/v Ear Drops, Suspension Active Ingredients Gentamicin sulfate, Hydrocortisone Acetate
Medicine Name HYTRIN Tablets 10mg Active Ingredients Terazosin monohydrochloride dihydrate
Medicine Name HYTRIN Tablets 2mg Active Ingredients Terazosin monohydrochloride dihydrate
1 - 0 of 44 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 7 August 2015 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

The following sections 2, 4.1- 4.9, 5.1, 5.3, 6.6, & 10 of the SPC were updated

Updated on 7 August 2015 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

The following sections 2, 4.1- 4.9, 5.1, 5.3, 6.6, & 10 of the SPC were updated

Updated on 7 August 2015 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Supply through pharmacy only

Updated on 15 June 2012 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 2 (QUANTITATIVE AND QUALITATIVE COMPOSITION), the following statements have been added:

  

Excipient: Each tablet also contains 110.467 mg lactose monohydrate.

 

For a full list of excipients, see section 6.1.


 

 

In section 3 (PHARMACEUTICAL FORM), the following statement has been added:

  

The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses

 

 

In section 4 (Therapeutic indications), the following wording has been removed:

Route of administration
 

Oral

 


 

In section 4.2 (Posology and method of administration), the following statements have been added:

 

Route of administration
Oral

 


 

In Section 6.6 the heading has been changed to:

Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product


 

 

In section 10 (DATE OF PARTIAL REVISION OF THE TEXT) the following date has been added:

 

October 2008

 

 

Updated on 15 June 2012 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

In section 2 (QUANTITATIVE AND QUALITATIVE COMPOSITION), the following statements have been added:

  

Excipient: Each tablet also contains 110.467 mg lactose monohydrate.

 

For a full list of excipients, see section 6.1.


 

 

In section 3 (PHARMACEUTICAL FORM), the following statement has been added:

  

The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses

 

 

In section 4 (Therapeutic indications), the following wording has been removed:

Route of administration
 

Oral

 


 

In section 4.2 (Posology and method of administration), the following statements have been added:

 

Route of administration
Oral

 


 

In Section 6.6 the heading has been changed to:

Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product


 

 

In section 10 (DATE OF PARTIAL REVISION OF THE TEXT) the following date has been added:

 

October 2008

 

 

Updated on 27 August 2008 PIL

Reasons for updating

  • New SPC for new product

Updated on 27 August 2008 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Supply through pharmacy only